| Literature DB >> 31641369 |
Guangyu Yan1, Fei Li1, Christelle Elia2, Yating Zhao3, Jiangguang Wang3, Zhiheng Chen3, Hong Yuan1, Yao Lu1,2.
Abstract
BACKGROUND: Lipid accumulation product (LAP) is an index describing the overaccumulation of lipid. Baseline LAP was used for type 2 diabetes (T2D) prediction in previous studies. But the longitudinal trajectories of LAP, which reflect the efficacy of patients' lipid-lowering treatment and lifestyle improvement, have rarely been studied. The aim of this study is to explore the association of lipid accumulation product trajectories with 5-year incidence of type 2 diabetes.Entities:
Keywords: GLM; Lipid accumulation product; Trajectory; Type 2 diabetes
Year: 2019 PMID: 31641369 PMCID: PMC6802349 DOI: 10.1186/s12986-019-0399-7
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Fig. 1A flow diagram of participant screening and enrollment
Baseline characteristics according to LAP trajectories
| Variablesa | Total | Low trajectory | Moderate trajectory | High trajectory | |
|---|---|---|---|---|---|
| Age (years) | 42.0 (32.0–57.0) | 40.0 (31.0–57.0) | 47.0 (38.0–60.8) | 40.0 (33.0–48.0) |
|
| Male (%) | 2438 (54.1) | 1723 (47.4) | 648 (81.0) | 67 (97.1) |
|
| BMI (kg/m2) | 23.4 (20.9–25.6) | 22.5 (20.5–24.7) | 26.3 (24.6–28.0) | 27.3 (25.4–29.2) |
|
| WC (cm) | 80.0 (71.0–87.0) | 76.0 (70.0–84.0) | 89.0 (85.0–94.0) | 92.0 (88.0–95.8) |
|
| Han ethnicity (%) | 4339 (96.6) | 3500 (96.5) | 773 (97.2) | 66 (95.7) | 0.513 |
| Current smoker (%) | 990 (26.6) | 614 (20.5) | 331 (49.9) | 45 (75.0) |
|
| Current alcohol drinker (%) | 2031 (60.2) | 1490 (55.0) | 487 (80.0) | 54 (90.0) |
|
| Married status (%) | 3412 (86.4) | 2677 (84.5) | 680 (94.2) | 55 (93.2) |
|
| Family history of diabetes (%) | 347 (7.7) | 279 (7.7) | 59 (7.4) | 9 (13.0) | 0.235 |
| Hypertension (%) | 947 (21.7) | 634 (18.0) | 295 (37.7) | 18 (27.3) |
|
| Use of antihypertensive (%) | 407 (9.0) | 285 (7.8) | 118 (14.8) | 4 (5.8) |
|
| LAP | 19.7 (9.9–36.0) | 15.4 (8.0–25.7) | 56.6 (43.0–75.8) | 118.5 (86.6–200.1) |
|
| Fasting blood concentrations of | |||||
| Glucose (mmol/l) | 5.0 (4.7–5.3) | 4.9 (4.7–5.3) | 5.2 (4.8–5.6) | 5.2 (4.8–5.8) |
|
| Total cholesterol (mmol/l) | 4.7 (4.2–5.3) | 4.6 (4.1–5.2) | 5.1 (4.5–5.8) | 5.7 (4.9–6.3) |
|
| Triglycerides (mmol/l) | 1.14 (0.79–1.67) | 1.00 (0.73–1.35) | 2.28 (1.71–2.98) | 4.5 (3.2–8.1) |
|
| HDL (mmol/l) | 1.40 (1.15–1.71) | 1.48 (1.23–1.78) | 1.14 (0.96–1.32) | 1.04 (0.85–1.21) |
|
| Hemoglobin (g/L) | 133.0 (124.0–144.0) | 131.0 (123.0–142.0) | 144.0 (135.0–150.0) | 146.0 (138.0–154.0) |
|
| Creatinine (μmol/L) | 66.0 (54.0–78.0) | 62.0 (53.0–75.0) | 75.0 (66.0–84.0) | 74.0 (65.0–83.0) |
|
| Uric acid (μmol/L) | 283.0 (221.0–350.0) | 263.0 (210.0–327.0) | 359.0 (305.0–418.0) | 390.0 (332.0–451.5) |
|
BMI body mass index, WC waist circumference, LAP lipid accumulation product, HDL high-density lipoprotein cholesterol
aContinuous variables were summarized as median (interquartile range)
bP values are calculated by Kruskal–Wallis test for continuous variables and chi-square test for categorical variables
Fig. 2Three LAP trajectories determined by the best-fit model from 2011 to 2016
Relative risk and 95% confidence interval for the 5-year incidence of type 2 diabetes according to LAP trajectories and baseline LAP
| Variables |
| Cases (%) | Model 1a | Model 2b | Model 3c |
|---|---|---|---|---|---|
| LAP trajectories | 4508 | 169 (3.8) | |||
| Trajectory 1: low | 3639 | 78 (2.1) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Trajectory 2: moderate | 800 | 80 (10.0) | 3.51 (2.57–4.80) | 2.56 (1.78–3.70) | 1.95 (1.41–2.70) |
| Trajectory 3: high | 69 | 11 (15.9) | 7.68 (4.12–14.32) | 5.20 (2.77–9.76) | 2.20 (1.12–4.30) |
|
|
|
| |||
| Baseline LAP (groups)d | 4179 | 154 (3.7) | |||
| First group: (< 42.4) | 3368 | 69 (2.1) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Second group: (42.4 ≤ ~ < 121.6) | 748 | 78 (10.4) | 3.60 (2.61–4.96) | 2.56 (1.76–3.73) | 1.73 (1.25–2.38) |
| Third group: (≥121.6) | 63 | 7 (11.1) | 4.62 (2.21–9.66) | 2.61 (1.15–5.95) | 1.47 (0.66–3.31) |
|
|
| 0.006 | |||
| Baseline LAP (tertiles) | 4179 | 154 (3.7) | |||
| First tertile: (< 12.7) | 1393 | 12 (0.9) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Second tertile: (12.7 ≤ ~ < 29.3) | 1394 | 27 (1.9) | 1.33 (0.67–2.66) | 1.04 (0.52–2.07) | 1.03 (0.52–2.03) |
| Third tertile: (≥29.3) | 1392 | 115 (8.3) | 4.90 (2.65–9.06) | 2.93 (1.52–5.65) | 1.91 (0.97–3.74) |
|
|
| 0.007 |
LAP lipid accumulation product
aModel 1: adjusted for baseline age, gender, race, current smoking, current alcohol drinking, and married status
bModel 2: further adjusted for baseline diagnosis of hypertension, use of antihypertensive, total cholesterol, high-density lipoprotein cholesterol, hemoglobin, creatinine, and uric acid
cModel 3: further adjusted for baseline blood glucose and family history of diabetes
dFrom first to the third group, the proportions of subjects were 80.6, 17.9, and 1.5%, respectively. The divisions were consistent with the proportions of different LAP trajectories